AIM Stock Analysis: Buy, Sell, or Hold?
AIM - AIM ImmunoTech Inc.
$0.35
-0.01 (-3.72%)
▼
5d:
-13.89%
30d:
+47.39%
90d:
-63.98%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When AIM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AIM is down 13.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AIM is down 13.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AIM is currently trading at $0.35, which is considered slightly low relative to its 30-day fair value range of $0.28 to $0.60.
Technical Outlook: Technically, AIM is in a strong downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.25 (+1345.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AIM is in a strong downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.25 (+1345.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.28 -
$0.60
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 1345.9% below Wall St target ($5.25)
- WARNING: Recommendation downgraded due to -13.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.28 -
$0.60
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.35
Resistance Level
$0.49
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.70
Wall Street Target
$5.25
(+1345.9%)
Revenue Growth (YoY)
37.5%
Share & Embed Analysis
Last updated: June 24, 2026 1:40 PM ET
Data refreshes hourly during market hours. Next update: 2:40 PM
Data refreshes hourly during market hours. Next update: 2:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AIM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
